These gas and propane generators will provide enough power to get you through some tough days.

Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

General information on the simulation of radionuclides in the marine environment using dispersion and transport models was compiled. This is intended for scientists in Member States considering ...

NAA with short half-life radionuclides enables an analysis turnaround time of one working day in principle. It also enables the detection of many important elements that cannot otherwise be measured ...